Why the study?
Approaches to personalizing dual antiplatelet therapy based on functional or genetic testing have evolved, particularly regarding therapy escalation, de-escalation, or shortening duration according to thrombotic and bleeding risks.
Answers are grounded in this paper and cite their sources.
Personalized antiplatelet therapy using functional or genetic testing allows for tailored DAPT duration and intensity, balancing thrombotic and bleeding risks in post-PCI patients.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Khakimova et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: